Want to see IBIO full AI Analyst Report?
IBIO Stock Chart & Stats
$1.47
$0.03(2.14%)
At close: 4:00 PM EDT
$1.47
$0.03(2.14%)
Day’s Range― - ―
52-Week Range$0.77 - $3.82
Previous CloseN/A
Volume1.21M
Average Volume (3M)599.29K
Market Cap
$73.33M
Enterprise Value$11.63
Total Cash (Recent Filing)$88.04M
Total Debt (Recent Filing)$2.20M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding60,853,560
10 Day Avg. Volume407,090
30 Day Avg. Volume599,287
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.12
Price to Sales (P/S)1821.05
P/FCF Ratio-7.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.33Price Target Upside262.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$28.57K
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage reduces near-term balance-sheet stress and leaves more flexibility than a highly indebted biotech would have. The modest debt burden may help preserve strategic options while iBio funds development, although it does not eliminate the need to finance ongoing losses.
Experienced Clinical LeadershipAdding an experienced Chief Medical Officer strengthens clinical, medical-affairs and regulatory leadership as iBio advances its obesity and cardiometabolic pipeline. Her background across major biopharmaceutical companies and universities could improve execution as programs move toward later-stage development.
Promising Obesity Candidate DataThe preclinical IBIO-610 results provide differentiated pipeline optionality, including durable target suppression, fat-selective weight loss and improved lean-mass preservation with semaglutide. If replicated in further development, these characteristics could support a distinct position in obesity treatment.
Bears Say
Minimal, Declining Revenue And Deep LossesThe very small and declining revenue base shows that iBio has not yet established meaningful commercial traction, while operating costs greatly exceed sales. Deep EBIT and net losses reduce financial resilience and indicate that the company remains dependent on successful pipeline advancement rather than current operations.
Persistent Cash BurnSustained negative operating and free cash flow means iBio is consuming cash to support its business and development activities rather than self-funding them. Continued burn can require additional financing over the coming quarters, potentially limiting strategic flexibility and increasing pressure on execution.
Poor Capital Efficiency And Variable FinancingSharply negative return on equity indicates that shareholder capital is not currently generating profits, weakening the economic efficiency of the business. The historical swings in leverage and equity also suggest that financing conditions and capital structure can change materially, complicating long-term planning.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.77 and its highest was $3.82 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $73.33M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is Nov 17, 2026 which is in 65 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Aug 28, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.069 by $0.019.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.07.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 60,853,560 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.069. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.33 (262.81% Upside)
$5.33 (262.81% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
327.47%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ibio Inc
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.33
▲(262.81% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
0.50% Insiders
2.14% Mutual Funds
34.68% Other Institutional Investors
59.14% Public Companies and
Individual Investors